-
Something wrong with this record ?
Common variable immunodeficiency patients display elevated plasma levels of granulocyte activation markers elastase and myeloperoxidase
J. Litzman, Z. Chovancová, P. Bejdák, M. Litzman, Z. Hel, M. Vlková,
Language English Country England, Great Britain
Document type Journal Article
Grant support
NV15-28732A
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Directory of Open Access Journals
from 2017
PubMed Central
from 2016
Europe PubMed Central
from 2016
ProQuest Central
from 2016-03-01
Health & Medicine (ProQuest)
from 2016-03-01
ROAD: Directory of Open Access Scholarly Resources
from 1988
- MeSH
- Common Variable Immunodeficiency blood diagnosis drug therapy MeSH
- Biomarkers blood MeSH
- Adult MeSH
- Immunoglobulins, Intravenous administration & dosage MeSH
- Leukocyte Elastase blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Peroxidase blood MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Common variable immunodeficiency disorders (CVIDs) represent a group of primary immunodeficiency diseases characterized by hypogammaglobulinemia and dysfunctional immune response to invading pathogens. Previous studies have indicated that CVID is associated with microbial translocation and systemic myeloid cell activation. The goal of this study was to determine whether patients with CVID display elevated systemic levels of markers of granulocyte activation and whether the levels are further influenced by intravenous immunoglobulin (IVIg) infusions. The plasma levels of granulocyte activation markers elastase and myeloperoxidase were determined using enzyme-linked immunosorbent assay (ELISA) in 46 CVID patients and 44 healthy controls. All CVID patients were in a stable state with no apparent acute infection. In addition, granulocyte activation markers' plasma levels in 24 CVID patients were determined prior to and 1 h following IVIg administration. Neutrophil elastase and myeloperoxidase plasma levels were significantly higher in CVID patients than in healthy controls. Systemic elastase levels were further increased following IVIg administration. In vitro stimulation of 13 CVID patients' whole blood using IVIg in a therapeutically relevant dose for 2 h resulted in a significant increase in plasma elastase levels compared to unstimulated blood. The data presented here indicate that CVID is associated with chronic granulocytic activation which is further exacerbated by administering IVIg. Increased myeloperoxidase and elastase levels may contribute to associated comorbidities in CVID patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19034644
- 003
- CZ-PrNML
- 005
- 20240909102237.0
- 007
- ta
- 008
- 191007s2019 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/2058738419843381 $2 doi
- 035 __
- $a (PubMed)30968712
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Litzman, Jiří $u 1 Department of Clinical Immunology and Allergology, St. Anne's University Hospital, Brno, Czech Republic. 2 Department of Clinicla Immunology and Allergology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 245 10
- $a Common variable immunodeficiency patients display elevated plasma levels of granulocyte activation markers elastase and myeloperoxidase / $c J. Litzman, Z. Chovancová, P. Bejdák, M. Litzman, Z. Hel, M. Vlková,
- 520 9_
- $a Common variable immunodeficiency disorders (CVIDs) represent a group of primary immunodeficiency diseases characterized by hypogammaglobulinemia and dysfunctional immune response to invading pathogens. Previous studies have indicated that CVID is associated with microbial translocation and systemic myeloid cell activation. The goal of this study was to determine whether patients with CVID display elevated systemic levels of markers of granulocyte activation and whether the levels are further influenced by intravenous immunoglobulin (IVIg) infusions. The plasma levels of granulocyte activation markers elastase and myeloperoxidase were determined using enzyme-linked immunosorbent assay (ELISA) in 46 CVID patients and 44 healthy controls. All CVID patients were in a stable state with no apparent acute infection. In addition, granulocyte activation markers' plasma levels in 24 CVID patients were determined prior to and 1 h following IVIg administration. Neutrophil elastase and myeloperoxidase plasma levels were significantly higher in CVID patients than in healthy controls. Systemic elastase levels were further increased following IVIg administration. In vitro stimulation of 13 CVID patients' whole blood using IVIg in a therapeutically relevant dose for 2 h resulted in a significant increase in plasma elastase levels compared to unstimulated blood. The data presented here indicate that CVID is associated with chronic granulocytic activation which is further exacerbated by administering IVIg. Increased myeloperoxidase and elastase levels may contribute to associated comorbidities in CVID patients.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a běžná variabilní imunodeficience $x krev $x diagnóza $x farmakoterapie $7 D017074
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a intravenózní imunoglobuliny $x aplikace a dávkování $7 D016756
- 650 _2
- $a leukocytární elastasa $x krev $7 D019272
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a peroxidasa $x krev $7 D009195
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Chovancová, Zita $u 1 Department of Clinical Immunology and Allergology, St. Anne's University Hospital, Brno, Czech Republic. 2 Department of Clinicla Immunology and Allergology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Bejdák, Petr $u 1 Department of Clinical Immunology and Allergology, St. Anne's University Hospital, Brno, Czech Republic. 2 Department of Clinicla Immunology and Allergology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 xx0322341
- 700 1_
- $a Litzman, Marek $u 3 Department of Economics, Faculty of Business and Economics, Mendel University in Brno, Brno, Czech Republic.
- 700 1_
- $a Hel, Zdeněk $u 4 Departments of Pathology and Microbiology, The University of Alabama at Birmingham, Birmingham, AL, USA.
- 700 1_
- $a Vlková, Marcela $u 1 Department of Clinical Immunology and Allergology, St. Anne's University Hospital, Brno, Czech Republic. 2 Department of Clinicla Immunology and Allergology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 773 0_
- $w MED00002332 $t International journal of immunopathology and pharmacology $x 2058-7384 $g Roč. 33 (2019), s. 2058738419843381
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30968712 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20240909102235 $b ABA008
- 999 __
- $a ok $b bmc $g 1451304 $s 1073194
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 33 $c - $d 2058738419843381 $e - $i 2058-7384 $m International journal of immunopathology and pharmacology $n Int. j. immunopathol. pharmacol. $x MED00002332
- GRA __
- $a NV15-28732A $p MZ0
- LZP __
- $a Pubmed-20191007